Treatments with resveratrol [253,254] and EGCG [255] have been shown to attenuate Aβ1–40 and slow cognitive decline in AD patients, and in stroke patients, reduce the levels of matrix metalloproteinase-9 (MMP-9) and matrix metalloproteinase-2 (MMP-2). Here, MMP9 is linked to Stroke.